Truveta

Just got back from DIA's 2025 #RealWorldEvidence Conference in San Diego—feeling energized after connecting with so many incredible leaders who are shaping the future of evidence generation. I had the privilege of sharing how Truveta Data is helping accelerate insights by delivering regulatory-grade real-world data—ahead of traditional trials and registries. From optimizing heart failure clinical trial design to label expansion studies for medical devices, we’re seeing how high-quality, timely data can close critical gaps in understanding treatment effectiveness and safety. A few takeaways that stood out to me: - Regulatory acceptance of RWE is growing. It’s an exciting time to see RWE becoming a trusted part of decision-making. - Transparency is essential. Clearly communicating data provenance, transformations, analytic methods, and study design is critical to building scientific trust. - Multi-modal data is the next frontier. To truly understand patient outcomes, we must move beyond structured EHRs and claims to include unstructured notes, imaging, and genomics. Truveta is at the forefront of this evolution, empowering researchers to generate real-world evidence with the quality, transparency, and speed needed to improve patient outcomes and advance medical innovation.

Medical device innovation demands evidence that’s fast, precise, and regulatory-grade. Legacy data sources like claims, chargemaster, and registries weren’t built for today’s needs—they lack device-level detail, clinical context, and timeliness. Truveta Data changes that: with daily updated EHR data from US health systems, device identity mapped to unique device identifiers (UDIs), and linked notes, images, and cost data, Truveta delivers a complete, transparent view of device use across populations and care settings. Our latest whitepaper explores how regulatory-grade, real-world data can help device companies: ✅ Support faster, more robust regulatory submissions ✅ Accelerate trial design and safety monitoring ✅ Demonstrate clinical and economic value Learn more: https://tr.vet/4n9BrhK

A new study from the Centers for Disease Control and Prevention used Truveta Data to study how doxycycline postexposure prophylaxis (doxy PEP)—a promising new strategy to prevent bacterial STIs—is being prescribed in real-world care. Using de-identified EHR data from 1 in 3 Americans, CDC researchers were able to evaluate how doxy PEP is documented in clinical practice—showing how real-world data can inform both clinical guidelines and public health policy. 🔍 Read more: https://tr.vet/47oVB2x

Thrilled to be named one of LinkedIn's Top Startups for the third year in a row 🎉 We're honored to be one of the many companies growing fast, attracting top talent, and shaping the future of work. We couldn’t be more grateful for the Truveta team making it happen. 💙 Thank you to our incredible employees, partners, and health system members for helping us reach this milestone—and for making Truveta an extraordinary place to grow and make an impact. 🔗 Join the Truveta team: https://tr.vet/46QZayh #LinkedInTopStartups

AI is unlocking a new frontier for what's possible in healthcare 📈 🔬 At Truveta, AI is transforming trillions of real-world health data points into insights that can change lives. The Truveta Language Model enables every diagnosis, note, and result to contribute to discovery and improved care and outcomes. With Truveta and the power of AI, entire organizations can learn faster, ask more, and accelerate breakthroughs. We’re just getting started 🚀

In just a couple weeks, Truveta will be in Boston for the 13th IMPACCT Real-World Evidence Summit! Don't miss VP of Partner Growth Conor Wyand share how linked, real-time EHR and claims data set a new standard for real-world evidence. 📍 Boston, MA | 🗓️ Tuesday, October 28 | 🕚 10:40am 🔗 Full agenda here: https://tr.vet/4nSCELi

In recognition of #WorldMentalHealthDay, we’re highlighting the importance of depression research. With more than 10 million patient journeys with major depression, Truveta Data provides real-world insights to help evaluate treatment effectiveness, access, and outcomes in practice. 🔗 Learn more about what's possible in mental health research: https://tr.vet/3L30mG9

🔎 Transparency is the new standard for regulatory-grade real-world evidence. The FDA has launched a new resource cataloging more than a decade of case studies where RWE informed approvals, safety communications, and labeling updates. This initiative signals a growing expectation: regulators want evidence that is transparent, reproducible, and fit-for-purpose. We've invested deeply to deliver exactly that: Truveta Data is directly traceable to its source, fully auditable, and trusted by regulators. With complete provenance, audit-ready workflows, and the most complete real-time EHR dataset in the US, we provide regulatory-grade RWD that meets and exceeds FDA standards. 📖 Read our perspective on the FDA’s new initiative: https://tr.vet/4779l1H

🩺 🔬 Medical device research is evolving. Until now, device companies had to choose: cost data without clinical context, or clinical context without cost. With Truveta Data, you get it all. ✔ Individual device data ✔ Procedure logs ✔ Clinical notes, labs, images, vitals ✔ Claims and mortality records Surface insights across the full care journey—from diagnosis, through surgery, to recovery—with research-ready, regulator-trusted data. Learn more: https://tr.vet/4nAt145